Cardihab announced as successful grant recipient in $3.7 million funding pool through ANDHealth+ program

Copy of Linkedin image ANDHealth+ announcement (800 × 400 px) (1)

Cardihab is one of four successful digital health companies awarded a share of $3.7M from the Australian Government’s Medical Research Future Fund (MRFF).  The funds are being invested into high-growth potential digital health companies, supporting them to develop and release new products and expand into global markets, through digital health commercialisation program, ANDHealth+.  

Funded by the MRFF, the ANDHealth+ program is delivered by ANDHealth, Australia’s leading digital health commercialisation organisation, providing Australia’s most promising digital health start-ups access to up to $3.7M in non-dilutive investment, alongside substantial industry mentoring and support, across a two-stage investment process.

Cardihab, successfully completed a rigorous process of qualification, including assessments by leading Australian and international investors and digital health executives, and has been selected to move into the next stage of the process.

ANDHealth CEO and Managing Director Bronwyn Le Grice said, “These companies are perfect examples of how Australian businesses are using technology to solve real health problems faced by millions of people locally and around the world. This investment will support these companies to secure the clinical evidence and customers they need to create better health and patient outcomes on a global scale."

“Due to the limited funding pools for digital health companies in Australia, ANDHealth+ is a highly competitive program that selects world-class, evidence-based technologies, as assessed by an expert industry panel and international investment committee.”

Ms LeGrice says the exhaustive process is designed to identify the companies and technology with the greatest chance of commercial growth and beneficial effect.  

Cardihab CEO Helen Souris says, “to be successful in a program like this is an incredible testament to the quality of our solution, the work of our dedicated team, and the potential of our technology to have a positive impact on patients here in Australia, as well as globally.” 

"Cardihab is thrilled to continue to receive funding and advice as part of the ANDHealth+ program. We will leverage this support to prepare our digital therapeutic for international markets and gather additional clinical evidence to further demonstrate our impact on patients needing cardiac rehabilitation."

We look forward to continuing our productive collaboration with ANDHealth and partners during the next phase of the program.

For more information about our programs and opportunities please contact us.

 

READ MORE at ANDHealth News.

 

Cardihab developing intuitive AI driven analytics solution set to revolutionise patient care

Copy of Linkedin image AC Grant announcement

Healthcare providers and patients will soon benefit from an intuitive health data analytics product called C.R.O.P.S which is designed to unlock insights gained from digital health platform Cardihab®.  

Cardihab were recently awarded $782,768 in matched funding from the Australian Government’s Entrepreneurs’ Programme - Accelerating Commercialisation, to further develop data analytics capabilities and products within the Cardihab ecosystem under the product name C.R.O.P.S—Cardiac Rehabilitation Outcomes and Process Synopsis. 

The project titled ‘C.R.O.P.S - impact via health data and augmented intelligence in care’ has the potential to transform the efficiency of care and outcomes for patients and health services by automating much of the collation and analysis of  complex health data entered by patients and clinicians. It will also leverage Artificial Intelligence (AI)  and Machine Learning (ML) systems to process the real world data from Cardihab’s patient care plans to identify signals or trends in patient behaviour that could indicate positive progress and/or deterioration that would require clinical attention.  

The project will address key challenges of efficiency in care delivery and scalability, by both reducing the administrative and analytical burden of governance reporting as well as providing an augmented and intelligent point of care solution that will give clinical teams valuable decision making tools. 

Cardihab CEO Helen Souris says this is a highly sought after solution that is targeting the growing challenge of extracting meaning from the petabytes of health data that are in our health system, and one that promises to transform current care practices for the better. 

“Many of our customers have expressed a desire for a product like this to help efficiently extract insights from the huge amount of health data that is generated through the daily use of our platform.  We’re building a suite of tools to support clinical and business decision making, that will ultimately enable more patients to have access to care.”

Accelerating Commercialisation is a service under the AusIndustry Entrepreneurs’ Programme, that provides organisations with advice and funding up to $1 million, to assist in the development and commercialisation of products that represent genuine innovation and a compelling value proposition backed up by market demand.

Cardihab CEO Helen Souris speaks to Talking HealthTech about the need for a data analytics solution to transform patient care and outcomes.